文献速递艾滋病与性传播感染

在澳大利亚大型HIV暴露前预防试验PrEPX入组时,以性传播感染作为HIV风险标志评估暴露前预防资格标准

Evaluation of Preexposure (PrEP) Eligibility Criteria, Using Sexually Transmissible Infections as Markers of Human Immunodeficiency Virus (HIV) Risk at Enrollment in PrEPX, a Large Australian HIV PrEP Trial.
PubMed 文献 · Clin Infect Dis · 2018-01-01

在澳大利亚PrEPX试验的1774名入组者中,10.2%检测出性传播感染。资格标准1-4预测了性传播感染诊断,标准5和6未预测。不符合资格标准但临床评估后入组者中性传播感染患病率为7.1%,提示请求暴露前预防但不符合标准者仍可能需要暴露前预防。

要点

  • 资格标准1-4预测入组时性传播感染诊断,标准5和6未预测。
  • 不符合资格标准但经临床评估入组者,性传播感染患病率为7.1%。
  • 研究结果支持当前指南推荐的暴露前预防资格标准。

核心结论

  • 资格标准1-4预测了性传播感染诊断,但资格标准5和6未预测。
  • 研究结果支持当前指南推荐的暴露前预防资格标准。
  • 不符合资格标准但经临床评估入组者中性传播感染患病率较高,提示请求暴露前预防但不符合资格标准者仍可能需要暴露前预防。

研究设计与样本

  • 研究纳入澳大利亚PrEPX试验的1774名参与者,计算调整比值比(aOR)评估资格标准是否预测入组时性传播感染诊断。

主要发现

  • 1774名参与者中10.2%检测出性传播感染。
  • 与HIV阳性固定性伴侣且病毒载量可检测者发生无套肛交的aOR为2.5(95%CI 1.4-4.4)。
  • 与临时性伴侣发生接受性无套肛交的aOR为1.8(95%CI 1.3-2.5)。
  • 既往性传播感染史的aOR为1.8(95%CI 1.3-2.5)。
  • 甲基苯丙胺使用的aOR为2.1(95%CI 1.4-3.0)。

关键数值与推荐

  • 资格标准1:与HIV阳性固定性伴侣且病毒载量可检测者发生无套肛交,aOR 2.5(95%CI 1.4-4.4)。
  • 资格标准2:与临时性伴侣发生接受性无套肛交,aOR 1.8(95%CI 1.3-2.5)。
  • 资格标准3:既往性传播感染史,aOR 1.8(95%CI 1.3-2.5)。
  • 资格标准4:甲基苯丙胺使用,aOR 2.1(95%CI 1.4-3.0)。
  • 资格标准5:安全套使用失败,aOR 0.8(95%CI 0.6-1.1);资格标准6:未行包皮环切时插入性无套肛交,aOR 1.0(95%CI 0.7-1.4)。

临床怎么用

  • 研究结果支持使用当前指南推荐的暴露前预防资格标准。
  • 不符合资格标准但请求暴露前预防者经临床评估后入组,其性传播感染患病率为7.1%,提示该人群仍可能需要暴露前预防。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: To determine participants' human immunodeficiency virus (HIV) risk, the Australian preexposure prophylaxis (PreEPX) trial used 6 eligibility criteria derived from the US Centers for Disease Control and Prevention PrEP guidelines. Participants who fulfilled no eligibility criteria could be enrolled if clinically assessed to need PrEP. This study evaluated whether PREPX eligibility criteria correlated with biological HIV risk markers-namely, syphilis, anorectal chlamydia, or anorectal gonorrhea (sexually transmitted infections [STIs]). METHODS: We calculated adjusted odds ratios (aORs) to assess whether eligibility criteria predicted STI diagnoses at enrollment. RESULTS: We included 1774 participants, of whom 10.2% tested positive for STIs. Eligibility criteria predicted STI diagnoses as follows: (1) aOR 2.5 (95% confidence interval [CI], 1.4-4.4) for condomless anal intercourse (CLAI) with an HIV-positive regular sexual partner (RSP) with detectable viral load; (2) aOR 1.8 (95% CI, 1.3-2.5) for receptive CLAI with casual sexual partners; (3) aOR 1.8 (95% CI, 1.3-2.5) for previous STIs; (4) aOR 2.1 (95% CI, 1.4-3.0) for methamphetamine use; (5) aOR 0.8 (95% CI, .6-1.1) for unsuccessful condom use; and (6) aOR 1.0 (95% CI, .7-1.4) for insertive CLAI when uncircumcised. Of participants enrolled outside eligibility criteria, 7.1% had STIs. CONCLUSIONS: Eligibility criteria 1-4 predicted diagnoses of STIs, but eligibility criteria 5 and 6 did not. Our findings support the use of PrEP eligibility criteria recommended in current guidelines. Participants enrolled outside the eligibility criteria had substantial prevalence of STIs, suggesting that people who request PrEP but do not fulfill eligibility criteria may nonetheless need PrEP.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Cornelisse VJ, Fairley CK, Stoove M, et al. Evaluation of Preexposure (PrEP) Eligibility Criteria, Using Sexually Transmissible Infections as Markers of Human Immunodeficiency Virus (HIV) Risk at Enrollment in PrEPX, a Large Australian HIV PrEP Trial. Clin Infect Dis. 2018. PMID: 29741665. doi:10.1093/cid/ciy370

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。